2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Sunday, November 5, 2017

2:30PM-4:00PM: Abstract Number: 892

Health-Related Quality of Life in Patients with Giant Cell Arteritis Treated with Tocilizumab in a Randomized Controlled Phase 3 Trial

Vasculitis I: Clinical Trials and Outcomes

2:30PM-4:00PM: Abstract Number: 867

Highly Sensitive Cardiac Troponin-I in Peripheral Blood Predicts Cardiovascular Events in Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects I: Cardiac Comorbidities

2:30PM-4:00PM: Abstract Number: 858

Identification of Clinically Relevant Pain Profiles in Individuals with Active RA

Pain – Basic and Clinical Aspects Oral

2:30PM-4:00PM: Abstract Number: 859

Identifying Pain Susceptibility Phenotypes in Those Free of Knee Pain with or at Risk for Knee Osteoarthritis and Their Relation to Developing Knee Pain

Pain – Basic and Clinical Aspects Oral

2:30PM-4:00PM: Abstract Number: 864

IL-9-Producing Innate Lymphoid Cells – Keyplayers That Orchestrate Resolution of Chronic Inflammation in Arthritis

Rheumatoid Arthritis – Animal Models

2:30PM-4:00PM: Abstract Number: 850

Immune Checkpoint Inhibitors and Inflammatory Myopathies: Data from the US Food and Drug Administration Adverse Event Reporting System

Muscle Biology, Myositis and Myopathies

2:30PM-4:00PM: Abstract Number: 862

iNKT Mediated Immunoregulatory Feedback Control Development of Autoimmune Arthritis in Mice

Rheumatoid Arthritis – Animal Models

2:30PM-4:00PM: Abstract Number: 831

Interferon-Alpha Disrupts Tolerance in a Mouse Model of B Cell Anergy

B Cell Biology and Targets in Autoimmune Disease

2:30PM-4:00PM: Abstract Number: 866

Interferon-Alpha Overexpression Triggers an Expansion of Highly Suppressive Regulatory T Lymphocytes Protecting Against Experimental Arthritis

Rheumatoid Arthritis – Animal Models

2:30PM-4:00PM: Abstract Number: 865

Lasp-1 Regulates Cell-Matrix and Cell-Cell Contacts in Arthritic Mouse Models

Rheumatoid Arthritis – Animal Models

2:30PM-4:00PM: Abstract Number: 891

Long-Term Efficacy and Safety of Tocilizumab in Patients with Refractory Takayasu Arteritis Treated Continuously over 52 Weeks: Results from Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial and Open-Label Extension in Japan

Vasculitis I: Clinical Trials and Outcomes

2:30PM-4:00PM: Abstract Number: 877

Modification of the Classification Criteria for Primary Sjögren Syndrome: An International Vignette Survey

Sjögren's Syndrome I: Clinical Assessment and Trial Outcomes

2:30PM-4:00PM: Abstract Number: 840

Mortality Post Hip Fracture in Rheumatoid Arthritis Compared to General Population Controls, a Population-Based Study

Epidemiology and Public Health I: Lung, Bone, and Infection Outcomes

2:30PM-4:00PM: Abstract Number: 872

Myocardial Abnormalities Improve in RA Patients Treated Actively – a Cardiac MRI Follow-up Study

Rheumatoid Arthritis – Clinical Aspects I: Cardiac Comorbidities

2:30PM-4:00PM: Abstract Number: 841

Optimal Regimens of Sulfamethoxazole-Trimethoprim for Chemoprophylaxis of Pneumocystis Pneumonia in Patients with Systemic Rheumatic Diseases: 52-Week Follow-up of a Non-Blinded, Randomized Controlled Trial

Epidemiology and Public Health I: Lung, Bone, and Infection Outcomes

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].